A procedure in which one or more parties (subject, investigator, sponsor) to the trial are kept unaware of which study drug the subject is given until the completion of the study.
Blinding occurs when researchers and/or subjects involved in a clinical trial do not know to which treatment group people are assigned. Blinding is used as a way of reducing bias. When both researchers and subjects don't know who is receiving which treatment, the study is referred to as "double-blind". When either the researchers or the subjects don't know who is receiving which treatment, the study is referred to as "single-blind".
When research participants are unaware of the assigned "treatment." In a single-blinded study, the subjects usually do not know what treatment they are receiving. In a double-blinded study, the subjects AND the investigators are unaware of the treatment assigned, as are the monitors and statisticians in some cases. Blinded studies are conducted to prevent the bias that can occur with known treatment assignments.
the concealment of group assignment (to either the treatment or control group) from the knowledge of patients and/or investigators in a clinical trial. Blinding eliminates the possibility that knowledge of assignment may affect patient response to treatment or investigator behaviors that may affect outcomes. Blinding is not always practical (e.g. when comparing surgery to drug treatment), but it should be used whenever it is possible and compatible with optimal patient care. A single-blind trial is one in which knowledge of group assignment is withheld only from patients; a double-blind trial is one in which the knowledge is withheld from patients and investigators.
The process through which one or more parties to a clinical trial are unaware of the treatment assignments. In a single blinded study, usually only the subject is unaware, and in a double blinded study, both the subject and the investigators are unaware of the assignment.
A lack of awareness of a subject's treatment group. Double-blinding is blinding of assessor as well as subject.
A procedure in which some or all of the participants in a clinical trial are not told of the treatment assignment/s, in order to prevent biasing the results.
The process through which one or more parties to a clinical trial are unaware of the treatment assignments. In a single-blinded study, usually the subjects are unaware of the treatment assignments. In a double-blinded study, both the subjects and the investigators are unaware of the treatment assignments. Also, in a double-blinded study, the monitors and sometimes the data analysts are unaware. "Blinded" studies are conducted to prevent the unintentional biases that can affect subject data when treatment assignments are known.
In randomized clinical trials, keeping secret which treatment is assigned to participants. When only the patient is kept unaware of his or her treatment assignment, the study is "single-blind." When the person administering treatment (e.g., the physician) also is unaware, the study is "double-blind." Additional layers of blinding can be added, as, for example, when a third individual (usually the evaluator of outcomes) also is unaware of treatment assignments.
Is the strategies used to ensure that, typically, trialists and/or trial participants do not know to which intervention group the participant has been allocated. Blinding safeguards the assignment sequence after allocation but is not always possible.
a method of conducting clinical trials so that some or all of the participants do not know whether subjects are taking active drug or placebo. Blinding is done to reduce bias in drug trials. See also double-blind.
an attempt to eliminate bias, "blinding" indicates that at least one party involved in the clinical trial is unaware of which patients are receiving the experimental treatment and which are receiving the control substance. Trials may be either single-blind (patients do not know which treatment they are receiving) or double-blind (neither the examining physicians nor the patients know which treatment they are receiving)
When the researchers, the participants, or both, do not know which people are getting which potential treatment being studied in a clinical trial. The process of blinding improves the accuracy of a study's results because no one is unconsciously influenced by the knowledge. If only researchers or only participants are blinded, the study is often called single blind. If both researchers and participants are blinded, the study is double blind. Because the terms "single blind" and "double blind" are imprecise, many researchers prefer to specify who is blinded -- investigators, participants, outcome assessors, or statisticians. (See http://www.acpjc.org/shared/glossary.htm)
A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). Single-blinding usually refers to the subject(s) being unaware, and double blinding usually refers to the subject(s), investigator(s), monitor, and, in some cases, data analyst(s) being unaware of the treatment assignment(s). In relation to an investigational medicinal product, blinding shall mean the deliberate disguising of the identity of the product in accordance with the instructions of the sponsor. Unblinding shall mean the disclosure of the identity of blinded products.
Study participants and/or study staff (therapists, outcome assessors) are unaware of who receives the experimental or control treatment.
in an experimental study, refers to whether patients, clinicians providing an intervention, people assessing outcomes, and/or data analysts were aware or unaware of the group to which patients were assigned. In the design section of Evidence-Based Nursing abstracts of treatment studies, the study is identified as blinded, with specification of who was blinded; unblinded, if all parties were aware of patients’ group assignments; or blinded (unclear) if the authors did not report or provide us with an indication of who was aware or unaware of patients’ group assignments.
A procedure in which one or more parties to the trial is kept unaware of the treatment assignment(s). Single-blinding usually refers to the subjects being unaware, and double-blinding usually refers to the subjects, investigators, monitor, and, in some case, data analysts being unaware of the treatment assignment(s).
A method to decrease bias in which the subject or investigator (single blinding) or both (double blinding) are unaware of the subject's assignment to interventional or control samples.
The practice of keeping the trial participants, care providers, data collectors, and sometimes those analyzing data unaware of which intervention is being administered to which participant. Blinding is intended to prevent bias on the part of study personnel. The most common application is double-blinding, in which participants, caregivers, and outcome assessors are blinded to intervention assignment. The term masking may be used instead of blinding.
A process used in clinical trials to assign individuals to the control group (to receive the standard treatment) or the test group (to receive the new treatment under study) without the individuals or the researchers knowing to which group they have been assigned. Blinding helps ensure that information collected in the study is true and not biased (flawed). In a single-blinded study, the individuals do not know whether the standard treatment or a new treatment is being given. In a double-blinded study, neither the individuals nor the researchers know which treatment is being given.